HemoRel® A
is a 250 IU preparation of clotting factor
VIII. HemoRel® A is indicated for
replacement of factor VIII in patients,
who have factor VIII deficiency i.e. patients
diagnosed with haemophilia A. Factor VIII
replacement is the therapy of choice for
clotting disorder in haemophilia A.
HemoRel®
A is an intermediate pure factor VIII.
It contains vWF (
325 IU) and fibrinogen (35-55% of total
protein). Intermediate pure factor VIII
(plasma derived) is three fold less likely
to give rise to inhibitors compared to
recombinant products and can be used for
vWF disease.
The product pack is user-friendly and
includes one 20 ml syringe, two needles,
water for injection, syringe filter and
spirit swab.
HemoRel® A
is a 250 IU preparation of clotting factor
VIII. HemoRel® A is indicated for
replacement of factor VIII in patients,
who have factor VIII deficiency i.e. patients
diagnosed with haemophilia A. Factor VIII
replacement is the therapy of choice for
clotting disorder in haemophilia A.
325 IU) and fibrinogen (35-55% of total
protein). Intermediate pure factor VIII
(plasma derived) is three fold less likely
to give rise to inhibitors compared to
recombinant products and can be used for
vWF disease.
